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Introduction
Hepatitis B virus can lead to acute and chronic infection.
Infection is transmitted by blood exposure, by sexual inter-
course, during childbirth, and in other ways that are not
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Summary
Objective: To evaluate the effectiveness of a recombinant hepatitis B vaccine used in endemic
areas of Colombia, as well as risk factors associated with hepatitis B virus (HBV) infection and
carriage after vaccine introduction.
Methods: A cross-sectional study was carried out in urban and rural areas of the Colombian
Amazon, a highly endemic area for hepatitis B infection. Children under 12 years of age and their
mothers were selected for the study using one-stage cluster sampling (N = 2145) and were
examined for HBV serological markers and antibodies against surface antigen (anti-HBs).
Results: There has been a reduction of 60—75% in the prevalence of HBV infection and hepatitis B
surface antigen (HBsAg) carriage since HBV vaccination was introduced. Receiving the first dose of
HBV vaccine at more than two months after birth was one of the factors associated with HBV
carrier status. Maternal HBV infection was also associated with infection in the child.
Conclusions: The recombinant Cuban hepatitis B vaccine has contributed to the reduction of the
infection in this highly endemic area, though further efforts are required to improve timely
vaccination for children at high risk.
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completely understood during early childhood. More than
300 million people are chronically infected with hepatitis B
virus (HBV) worldwide, with Asia and Africa carrying the
highest burden of the disease. Several areas in South America
have also been described as zones of high endemicity.1—3
There are five areas in Colombia where more than 70% of
the population has been infected with HBV. They are situated
on the Caribbean Coast, the Uraba Gulf, the Pacific Coast, the
Amazon Basin, and the Catatumbo River on the border with
Venezuela. A serological study made in 1980 on 60% of the
Colombian population found an HBsAg prevalence of from 3%
to 8% across different age groups. From these findings it is
estimated that there are 600 000 HBV carriers and 4 000 000
HBV infected people in Colombia.4—9
Following World Health Organization (WHO) recommen-
dations, in 1992 Colombia introduced a control program for
HBV infection using a recombinant vaccine. This program did
not include maternal screening or hepatitis B immune glo-
bulin (HBIG) for children born to hepatitis B surface antigen
(HBsAg) positive mothers. In order to assess the effectiveness
of this intervention, we carried out a sero-epidemiological
survey in the Colombian Amazon of children less than 10 years
of age and their mothers.
Methods
Study design
A one-stage cross-sectional survey was carried out in rural
and urban areas of the Colombian Amazon including Leticia,
Puerto Narin˜o, Araracuara, and Puerto Santander. Leticia and
Puerto Narin˜o are located in the area of the Amazon River,
and around half of the population (26 200 people) live in rural
areas and are very poor. Araracuara and Puerto Santander are
small villages (<1500 inhabitants) situated on the banks of
the Caqueta´ River, in the central area of the department, and
have been described as very high risk areas for HBV in
previous studies.10 Most of the Amazon’s people belong to
aboriginal tribes and live in precarious socio-economic and
sanitation conditions. The target population was composed
of children between 1 and 12 years of age, since they were in
the age group eligible for HBV vaccination.
Sample size
It was calculated that 2239 children would be needed to
estimate an HBsAg positive prevalence of 2% or more, with an
absolute precision of 0.8% and a design effect of 2.0. Children
were selected with probability proportional to size.
In urban and rural Leticia, we randomly selected 72
clusters out of 183. In rural Puerto Narin˜o, 11 out of 18
villages were randomly selected with probability propor-
tional to size. In urban Puerto Narin˜o, Araracuara, and Puerto
Santander, all households were included given their small
size.
Logistical aspects of fieldwork
Two health promoters visited every selected household and
recorded the family’s socio-economic conditions (crowding,
running water, social security). If one or more eligible chil-
dren were found, interviewers asked parents for a vaccina-
tion card. If a card was available, interviewers recorded the
number of vaccine doses received and the dates of vaccina-
tion. The child’s parents/guardians were asked to answer a
questionnaire on general risk factors for hepatitis B infection,
such as family and personal antecedents of clinical hepatitis
and family history of fulminant hepatitis, cirrhosis, or hepa-
tocellular carcinoma. The parents’ level of education,
breastfeeding practices, mother’s age at birth of first child,
mother’s age at birth of the child in question, the child’s
number of siblings, ethnic group, and the site where the child
was born were also recorded. Following signature of an
informed consent form by the child’s parent/guardian, a
blood sample was drawn from the child and the mother. Sera
were separated, stored frozen, and shipped to the Virology
Laboratory of the National Institute of Health for analysis of
hepatitis B virus markers.
Hepatitis B vaccination characteristics
Until 2001, Colombia used a recombinant hepatitis B vaccine
(Heberbiovac HB) manufactured in Cuba, which contains
20 mg of HBsAg.11 Three doses of HBV vaccine were recom-
mended at 2, 4, and 6 months of age. During the study period
no screening program was in place to detect HBsAg positive
pregnant women and no HBIG was offered.
Definitions for vaccination status
Completely vaccinated children were those holding a vaccina-
tion cardwhere threedoses ofHBVvaccinecouldbe identified.
Those who failed to fulfill these criteria were considered as
incompletely vaccinated. Children without written evidence
of vaccination were analyzed as a separate category.
Serological analysis
The children’s sera were processed for hepatitis B surface
antigen (HBsAg), total antibody to core antigen (anti-HBc),
antibody against core antigen IgM (IgM anti-HBc), and anti-
bodies against surface antigen (anti-HBs). All sera were
processed initially for HBsAg and anti-HBc. All sera positive
for both HBsAg and anti-HBc were further tested for IgM anti-
HBc. Anti-HBs titers were measured in a random sample of
children negative for both HBsAg and anti-HBc. Serological
screening was done using ELISA, while HBsAg carriage was
confirmed by neutralization. A similar scheme was used to
process the sera of the mothers.
Data handling and analysis
Epidemiological data were entered into several databases
using EpiInfo 6.04. The prevalence of HBV infection and
HBsAg positivity was calculated taking into account the
complex survey design.
We compared the present prevalence of HBV infection and
HBsAg carriage against prevalence found by previous studies
carried out in the same areas before the onset of the vacci-
nation program.10 Only prevalence in rural areas was com-
pared, since they were the only areas included in previous
data. Differences were stratified by age, sex, and place of
study.
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Variables potentially related to HBV infection and HBsAg
carriage were divided into the following categories: (1) child-
related variables (age, sex, gender, birth order, qualification
of the person delivering the child, and ethnic group); (2)
vaccination characteristics (time in days between birth and
the first dose of hepatitis B vaccine, time between first and
second dose, and time between second and third dose); (3)
mother-related variables (mother’s serological status for
hepatitis B, place where mother was born, and mother’s
history of clinical hepatitis). A separate analysis was done
for HBV infection and HBsAg carriage with each of these
categories. Odds ratios (OR) and 95% confidence intervals
(95% CI) were calculated using bivariate and multivariate
analysis (logistic regression). Variables found to be statisti-
cally related to HBV infection or HBsAg carriage were
included in a final multivariable model combining variables
from all categories. Logistic regression models were built
using the svy and the logistic command with cluster and
strata options.
Levels of anti-HBs antibody titers were related to several
variables (age, gender, ethnic group, breastfeeding, days
between doses of vaccine, and days between last dose and
sampling date) using two approaches. For the first one, titers
were treated as a continuous variable. Geometric means and
medians of titers were calculated for every category of
independent variable. Mean or median differences were
tested with non-parametric techniques such as the Krus-
kall—Wallis test. Those variables where anti-HBs differed
statistically across categories ( p < 0.1) were included in a
multivariable linear regression model.
In the second approach, children were categorized into
two groups according to their anti-HBs titers. One included
children with titers of <10 IU/l (not protected) and the
second, children with titers above that level. Bivariate ana-
lysis was done calculating ORs and 95% CIs as a measure of the
degree of the association. Those variables found related
( p < 0.1) in the bivariate analysis were included in a logistic
model.
Results
Among 2145 children, the overall prevalence of HBV infection
was 6.2% (95% CI 4.7—7.9) and HBsAg carriage was 1.1% (95%
CI 0.4—1.8%). The prevalences of infection and carriage were
higher in rural than in urban areas (9.2% and 2.6% vs. 2.6% and
0.17%, respectively) and in children 8 years and older, espe-
cially girls (see Figure 1).
A reduction (60—75%) in the prevalence of HBV infection
and carriage was observed for the period since the introduc-
tion of the vaccine, especially in the most endemic areas,
namely Araracuara. This reduction remained after stratifying
by age, sex, and place (see Table 1).
Ethnic origin, birthplace, and mother’s serological status
were found to affect the risk of HBV infection. Compared to
non-Indians, those belonging to an Indian tribe such as
Ticunas had a higher prevalence of HBV infection
(OR = 2.4, 95% CI 1.2—4.6). Belonging to an Indian group
other than Ticunas or Huitotos was associated with an even
higher risk when compared to non-Indians (OR = 4.6, 95% CI
2.4—8.6). Not being born in a hospital or health center
increased the risk of infection two-fold (OR = 2.4, 95%
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Figure 1 HBsAg prevalence (%) in rural areas by age and sex; all
children.
Table 1 Prevalence of hepatitis B infection and HBsAg found before and after the introduction of the hepatitis B vaccine, by age
group and place
Variable % Prevalence before
vaccinationa (n)
% Prevalence after
vaccinationb (n)
% Reduction
(95% CI)
Overall
Children 5—9 years, infection 32% (334) 9% (493) 72 (59—78) c
Children 10—14, infection 66% (189) 25% (160) 62 (49—72) c
Male children 5—9 years, infection 34% (157) 9% (247) 73 (59—83) c
Female children 5—9 years, infection 30% (177) 10% (246) 67 (48—78) c
Male children 10—14 years, infection 85% (144) 19% (87) 78 (64—85) c
Female children 10—14 years, infection 76% (135) 32% (72) 58 (40—70) c
Children 5—9 years, HBsAg+ 7% (334) 2% (495) 71 (35—84) c
Male children 5—9 years, HBsAg+ 8% (157) 2% (247) 75 (26—90) c
Araracuara and Puerto Santander
Children 5—9 years, infection 39% (111) 9% (125) 77 (54—86) c
Children 10—12 years, infection 87% (75) 28% (75) 68 (53—78) c
Children 5—9 years, HBsAg+ 9% (111) 2% (125) 73 (6—93)d
a Year 1992 (Ref. 10).
b Year 1999 (including only children from rural areas).
c p < 0.001.
d p < 0.05.
CI 1.5—4.1). Being born to an anti-HBc antibody positive
woman also increased the risk of infection (OR = 1.7, 95%
CI 1.1—2.6). None of the vaccine-related variables were
found to be associated with being HBV infected.
The variables associated with being a carrier were: not
being born in a hospital or health center (OR = 6.5, 95% CI
1.5—27.6), living with more than five siblings (OR = 3.3, 95%
CI 1.1—10.0), and being born to an anti-HBc positive mother
(OR = 3.5, 95% CI 1.0—11.8) (Table 2).
There were 1407 (66%) children with data available on
hepatitis B vaccination. Ninety-one percent of them (1277)
had completed the basic scheme for hepatitis B (three
doses). No statistical differences were found in HBsAg pre-
valence (1.2% vs. 0%) or infection (6% vs. 0%) between
children with complete or incomplete vaccination. Interest-
ingly, HBsAg prevalence among children without a vaccina-
tion card was very similar to the prevalence in documented
vaccinated children (1.1%). Time from birth to first dose of
HBV vaccine was related to HBsAg carriage even after con-
trolling for mother- and child-related variables. Receiving
the first dose of vaccine two months or later following birth
was related to an increase in the risk of HBsAg carriage,
especially among those receiving the vaccine after two years
of life (OR = 12.5, 95% CI 1.2—125.7) (see Table 2). Figure 2
shows the time differences between birth and first dose for
HBsAg carriers and non-carriers. The time between first and
second dose was longer in carriers from rural areas. Receiving
the second dose 35 days or more after the first was associated
with a two-fold increase in the risk of HBsAg carriage
(OR = 2.3, 95% CI 1.4—3.8). This association remained after
controlling for age, mother’s serological status, and number
of siblings.
Levels of anti-HBs were quantified in a sample of 263 non-
infected (HBsAg negative and anti-HBc negative) vaccinated
children. Titers ranged between 0 and 10 000 IU/l, 13% did
not have detectable anti-HBs, and 20% had titers under 10 IU/
l. Anti-HBs geometric mean and median concentrations
were 105 IU/l and 172 IU/l, respectively. Twelve percent of
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Table 2 Variables related to HBsAg prevalence, urban and rural areas
Variable People studied (n) HBsAg prevalence (n (%)) OR (95% CI) Adjusted OR (95% CI)
Child-related variables
Age groups (years)
1—3 435 1 (0.2) 1.0 1.0a
4—5 435 3 (0.7) 2.6 (0.3—27.2) 2.1 (0.2—22.8)
6—7 456 2 (0.3) 1.1 (0.1—11.5) 0.8 (0.1—10.0)
8—11 580 19 (3.0) 10.0 (1.2—90.8) 6.0 (0.6—65.4)
Birth received by
Doctor/nurse 1091 2 (0.2) 1.0 1.0a
Other 801 23 (2.7) 13.0 (3.0—57.0) 6.5 (1.5—27.6)
Number of siblings
1—5 1210 8 (0.5) 1.0 1.0a
6—20 356 11 (3.2) 6.2 (2.1—18.2) 3.3 (1.1—10.0)
Mother-related variables
Mother anti-HBc+
Yes 782 21 (2.4) 6.6 (1.8—25.1) 3.5 (1.0—11.8) b
No 895 3 (0.4) 1.0 1.0
Vaccine-related variables
Time from birth to first dose
0—60 days 495 1 (0.2) 1.0 1.0c
61—183 days 198 2 (1.2) 6.6 (0.5—90.4) 7.2 (0.5—115.1)
184—665 days 194 1 (0.6) 2.2 (0.1—40.4) 2.6 (0.1—50.0)
666—3253 days 199 7 (3.5) 8.9 (0.9—88.2) 12.5 (1.2—125.7)
Unknown 830 14 (1.2) 4.1 (0.5—35.4) 6.6 (0.6—66.4)
Time from first to second dose
28—35 days 467 3 (0.6) 1.0 1.0c
36—62 days 202 4 (1.9) 3.3 (1.2—8.9) 1.6 (0.7—3.8)
63—1877 days 426 7 (1.6) 2.8 (0.9—11.2) 1.2 (0.4—3.6)
Unknown 811 11 (1.0) 1.3 (0.3—4.7) 0.8 (0.2—3.7)
a OR adjusted by the remaining variables in the same category.
b OR adjusted by age group and place where mother was born.
c OR adjusted by age group, ‘birth received by’, number of siblings, mother’s infection status, and area (rural and urban).
Figure 2 Time (days) from birth to first hepatitis B vaccine
dose by HBsAg status; percentiles.
children had anti-HBs levels above 1000 IU/l. Two variables
were related to lack of anti-HBs: time interval since receiving
third dose and time interval from birth to first dose. Children
receiving their first dose within 14 days of birth had lower
levels of anti-HBs (geometric mean titer (GMT) = 33 IU/l vs.
66—174 among the other groups) (Table 3).
Discussion
There is a paucity of information in Latin America on the
effectiveness of hepatitis B vaccination programs, although
Brazil, Peru, Cuba, and Colombia have introduced them.12,13
Recently, a Peruvian group of researchers made an assess-
ment of the impact of the introduction of hepatitis B vaccine
in an endemic area of Peru, where they found a reduction in
the prevalence of HBV infection of from 83% to 92%. Com-
pliance with schedules was higher in the Peruvian study, since
it was a pre-introductory evaluation where the vaccination
process was supervised by researchers.14,15 The impact of the
vaccination program in our study is quite clear. Using the
representative population of the study of Cristancho10 for the
pre-vaccination era, there has been a highly significant
reduction in both infection and carriage, which is similar
to the reduction found in other recent studies in Pacific
countries (80%).16
Children over 8 years of age were more likely to be found
to be HBsAg carriers than those under 8 years. Children of
that age are more likely to refuse vaccine injections; also
children of that age were more likely to already have been
infected when HBV vaccination was started.10 Higher pre-
valence in older children has been found in other areas where
the hepatitis B vaccine has been introduced into the
Expanded Program on Immunization (EPI).17
No child born to a carrier mother was found to be an HBsAg
carrier in our study (0/24) despite none of them receiving
HBIG. This is low compared with other studies. Wilson et al.16
found that 27% of children born to an HBeAg positive mother
were HBsAg positive (13/48). This may be due to differences
in the chances of perinatal transmission in different parts of
the world, an issue related to the HBV-DNA levels, which also
vary among HBsAg positive mothers across regions.18—21
Mothers in Asian countries are more infectious to their
children than mothers in Africa (due to the higher levels of
HBV-DNA shown by Asian mothers), and our results suggest
that the perinatal transmission risk is lower for Amerindian
children compared to the Asians or Africans; this has been
found by others in the Brazilian Amazonia. Miranda Braga
et al. found an HBeAg prevalence of only 6% among 70 HBsAg
positive Indians examined in the Brazilian Amazon, which also
suggests lower levels of HBV-DNA in HBsAg carriers for this
region.22 It should also be recognized that ethnic and genetic
characteristics can play a role in explaining the differences in
perinatal transmission.17,22,23
Of note, in our study we also looked into the risk factors
for hepatitis B infection other than the mother’s serological
status. It is clear from our results that some of these factors
are still important predictors of HBV infection after vaccine
introduction. The number of siblings and the child’s birth
circumstances were the most important individual variables
identified. Children whose birth was not attended by a nurse/
doctor were twice as likely to be found HBsAg positive as
those who were attended by a doctor or nurse. This relation
was even stronger in rural areas where the OR increased to
more than 10-fold. It is likely that being born in a hospital or
health center results in receiving the first dose of hepatitis B
vaccine closer to the birth date. Another potential explana-
tion is that practices around home-attended births increase
the child’s risk of HBV infection.
Wewere able to demonstrate that delay in dose delivery is
associated with a higher likelihood of being HBsAg positive.
This aspect has not been frequently addressed by other
studies, either because vaccination timing was standardized
(clinical trials) or because there are few studies focusing on
time between doses. Former studies focusing on anti-HBs
titers as the main outcome have concluded that hepatitis B
vaccine can be delivered following almost any schedule (0-1-
3, 0-2-4, 0-1-6 months, etc.).24,25 In contrast, our results
show that while longer intervals can produce higher anti-HBs
titers, they might favor infection leading to the HBsAg carrier
status. Ruff et al. in Indonesia, showed that a delay of more
than a week between birth and first dose was associated with
a higher risk of becoming HBsAg positive.26 Other recent
studies have found no relation between HBV carriage and
vaccine delays, though they have found an important propor-
tion of children receiving vaccine doses later than recom-
mended.16
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Table 3 Anti-HBs levels by selected variables
Variable Number without
anti-HBs (%)
Number with anti-HBs
>10 mIU/ml (%)
Number with anti-
HBs 1000 mIU/ml (%)a
Anti-HBs GMT
[Median]
Time between birth and first dose p = 0.03 p = 0.03 p = 0.01
0—14 days 19 (33) 39 (67) 3 (5) 33 [68]
15—60 days 10 (19) 42 (81) 4 (8) 81 [169]
61—183 days 4 (8) 45 (92) 9 (18) 174 [153]
184—665 days 9 (20) 36 (80) 9 (20) 66 [110]
666—3253 days 10 (17) 49 (83) 14 (24) 145 [357]
Time between first and second dose p = 0.24 p = 0.14 p = 0.09
13—35 days 24 (23) 80 (77) 11 (11) 64 [119]
36—62 days 8 (17) 38 (83) 4 (9) 85 [148]
63—147 days 10 (17) 50 (83) 11 (18) 93 [142]
148—1877 days 9 (18) 41 (82) 11 (22) 126 [223]
a This category is included in the total number of those with anti-HBc levels >10 mIU/ml. GMT, geometric mean titer.
Our study did not find statistical differences in infection
rates between completely and incompletely vaccinated chil-
dren; however, one study in Taiwan found completeness of
vaccination as a predictor for HBsAg carriage.27 This may be
due to a lack of power in our sample since few carriers and
infected children were found. Also, children known to be
born to an HBsAg positive mother might have been pursued
more actively to ensure more adequate vaccination, thus
leading to a bias in our study. This last explanation is not
probable, since no screening for HBsAg in mothers was in
place in the Amazon from the start of the vaccination pro-
gram to the moment when our study was carried out. It could
also be related to the role that perinatal transmission has in
the Amazon, which is smaller than in Taiwan.
Other studies have found high proportions of vaccinated
children without detectable anti-HBs levels in countries
where regular programs are carried out. Poovorawan et al.
and Wilson et al. found prevalences in children without anti-
HBs to be similar to or even higher (21—50%) than those found
in our study (26%).16,28 These figures are higher than those
reported by clinical trials, and potential explanations include
cold chain factors and type of vaccine. A recombinant vac-
cine is used in the Amazon, and it has been shown that plasma
vaccine is more immunogenic especially when anti-HBs levels
are compared shortly after completing the scheme.29,30
The health workers poor knowledge of hepatitis B vacci-
nation guidelines might be related to the proportion of
children without anti-HBs in the present study. Most health
workers said that the vaccine should be applied in the
buttock, which is known to lead to a lower serological
response.31,32
Our study has several limitations. This is a cross-sectional
study where exposure and infection is measured at the same
time. This might impair causal inference since the temporal
relationship between vaccination and infection is not accu-
rate, i.e., several vaccinated childrenmay already have been
infected before they received the vaccine. Another limita-
tion is that no measurements of HBV-DNA levels were done in
the present study, which may be a residual confounder not
controlled in the analysis.
In summary, the process of implementing a new vaccine
against hepatitis B in the Colombian Amazon has been suc-
cessful. HBV vaccine has reached a high coverage especially
among children born after the implementation of the pro-
gram, though adherence to vaccine schemes should be
improved. There has been an important reduction in the
prevalence of HBV infection and HBsAg carriers, especially
among children aged 0 to 5 years, despite HBIG or screening
of pregnant women not being available. However, new vac-
cination strategies should be introduced in order to ensure an
adequate and timely access of the population to the vaccine,
especially in rural villages. Based on our recommendations,
the Amazon Health Service has started a serological screen-
ing for pregnant women aimed at providing more adequate
HBV vaccination schemes to children born to infected or
HBsAg carrier mothers.
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